Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN5668 + ubamatamab
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN5668 + ubamatamab is an investigational combination of two bispecific monoclonal antibodies developed for the treatment of ovarian cancer and other MUC16-expressing gynecologic malignancies. Both agents are designed to engage T cells for enhanced anti-tumor activity: - **REGN5668** is a human IgG4-based bispecific antibody that binds to MUC16 (a cell surface glycoprotein overexpressed in ovarian cancer) and CD28 (a T-cell costimulatory receptor), providing a costimulatory signal to T-cells in the tumor microenvironment[4]. - **Ubamatamab (REGN4018)** is a bispecific antibody targeting MUC16 and CD3, promoting direct T cell-mediated cytotoxicity against cancer cells expressing MUC16[2][4]. Their combination is hypothesized to synergistically stimulate T-cell activation and cytotoxicity, leading to improved anti-tumor immune responses compared to single-agent therapy. The combination is currently being evaluated in phase 1/2 trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with recurrent ovarian cancer and related malignancies[1][4][5][8][9].
- Other names
- MUC16 x CD28 bispecific antibody + MUC16 x CD3 bispecific antibody
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)MUC16 (Mucin-16)
Beyond the preview
Go deeper on REGN5668 + ubamatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN5668 + ubamatamab.